Showing results (81-90 of 144) with videos related to
Sort By:
Pageof 15
Archivos Espanoles De Urologia|July 13, 2026
Immunohistochemistry-Based Molecular Subtyping in Muscle-Invasive Bladder Cancer: Predicting Response to Neoadjuvant ChemotherapyLuis Pérez-Bartivas, Fernando Leiva-Cepas, David Ponferrada, et al.Molecular Diagnosis & Therapy|June 21, 2026
Considering Tumour Sidedness is Critical for Accurate Interpretation of Liquid Biopsy Results in Metastatic Colorectal CancerMarta Toledano-Fonseca, Icíar de la Fuente, María José Ortiz-Morales, et al.British Journal of Cancer|November 24, 2018
Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancerJesús García-Foncillas, Josep Tabernero, Elena Élez, et al.Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 12, 2025
Definition of lines of treatment in metastatic colorectal cancer: a Delphi consensusPilar García-Alfonso, Julia Alcaide-Garcia, Enrique Aranda Aguilar, et al.Journal of Cellular and Molecular Medicine|September 28, 2019
SWATH-based proteomics reveals processes associated with immune evasion and metastasis in poor prognosis colorectal tumoursLaura M López-Sánchez, Rafael Jiménez-Izquierdo, Jon Peñarando, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2007
Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors TrialEduardo Díaz-Rubio, Jose Tabernero, Auxiliadora Gómez-España, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2009
Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trialArnaud D Roth, Sabine Tejpar, Mauro Delorenzi, et al.Clinical Colorectal Cancer|March 20, 2018
A Randomized Phase II Study of Axitinib as Maintenance Therapy After First-line Treatment for Metastatic Colorectal CancerCristina Grávalos, Alfredo Carrato, María Tobeña, et al.Journal of the National Comprehensive Cancer Network : JNCCN|May 11, 2016
Quality Indicators to Assure and Improve Cancer Care in Spain Using the Delphi TechniqueCarlos Camps, Joan Albanell, Antonio Antón, et al.Cancer Biomarkers : Section a of Disease Markers|December 27, 2021
Association of miR-21 and miR-335 to microsatellite instability and prognosis in stage III colorectal cancerTania Calvo-López, Mateo Paz-Cabezas, Patricia Llovet, et al.Pageof 15